期刊文献+

P_2Y_(12)受体拮抗剂定量构效关系的研究 被引量:2

The QSAR research of P_2Y_(12) inhibitors
原文传递
导出
摘要 P2Y12受体拮抗剂是一类重要的抗血小板药物,研究分子活性与其结构参数的关系,对于合成新的P2Y12受体拮抗剂具有一定指导作用.选用178个结构多样的P2Y12受体拮抗剂分子作为数据集,随机选取了143个P2Y12受体拮抗剂作为训练集,剩余分子作为检验集.采用多元线性回归(MLR)方法和主成分回归分析(PCA)方法对每个分子的636个分子参数进行线性回归分析.MLR所建模型的结果为:训练集R2=0.800,检验集R2=0.834;PCA模型结果为:训练集R2=0.545,检验集R2=0.665.相比之下MLR法所建模型具有良好的预测性和可靠性.通过模型分析,确定了影响分子活性的关键因素.以上模型对筛选和合成新型高效P2Y12受体拮抗剂提供了一定理论指导. P2Y12 receptor antagonists are an important class of anti-platelet drugs.It has an important role in guiding the new synthesis of the P2Y12 receptor antagonists if we know the relationship between activities and structural parameters.In our work,178 P2Y12 receptor antagonist molecules were selected as the date set,with 143 molecules randomly selected as the training set and the rest as the test set.Using the multiple liner regression(MLR) and principle component analysis(PCA) methods,a 2D-QSAR study was carried out to explore the key factors that affect the activities of the P2Y12 receptor antagonist based on the 636 parameters of each molecule.The results show that MLR model presents a statistics result of training set R2=0.800,test set R2=0.834 and PCA model training set R2=0.545,test set R2=0.665.Comparing the two methods,it is shown that MLR exhibits good statistic results and the MLR model will be useful in predicting and developing P2Y12 receptor antagonists.
出处 《分子科学学报》 CAS CSCD 北大核心 2012年第5期389-394,共6页 Journal of Molecular Science
基金 国家自然科学基金资助项目(10801025)
  • 相关文献

参考文献1

二级参考文献21

  • 1谭丽玲,贾三庆,王明生,李虹伟,王雷,赵敏,沈潞华,贾宁,孙志军.急性冠脉综合征患者氯吡格雷抵抗的影响因素[J].中国心血管病研究,2006,4(9):680-682. 被引量:14
  • 2Hollopeter G,Jantzen HM,Vincent D,et al.Identification of the platelet ADP receptor targeted by antithrombotic drugs.Nature,2001,409:202-207.
  • 3Dorsam RT,Kunapuli SP.Central role of the P2Y12 receptor in platelet activation.J Clin Invest,2004,113:340-345.
  • 4Jakubowski JA,Winters KJ,Naganuma H,et al.A novel thienopyridine antiplatelet agent.A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.Cardivasc Drug Rev,2007,25:357-374.
  • 5Sugidachi A,Ogawa T,Kurihara A,et al.The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.J Thromb Haemost,2007,5:1545-1551.
  • 6Brandt JT,Payne CD,Wiviott SD,et al.A comparison of prasugrel and clopidogrel loading doses on platelet function:magnitude of platelet inhibition is related to active metabolite formation.Am Heart J,2007,153:66.e9-16.
  • 7Jernberg T,Payne CD,Winters KJ,et al.Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.Eur Heart J,2006,27:1166-1173.
  • 8Payne CD,Li YG,Small DS,et al.Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.J Cardiovasc Pharmacol,2007,50:555-562.
  • 9Wiviott SD,Trenk D,Frelinger AL,et al.Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention:the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.Circulation,2007,116:2923-2932.
  • 10Michelson AD,Frelinger AL 3rd,Braunwald E,et al.Pharmacodynamic assessment of plateIet inhibition by prasugrel vs.clopidogrel in the TRITON-TIMI 38 trial.Eur Heart J,2009,30:1753-1763.

共引文献3

同被引文献6

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部